BHC
BMRN icon

Bull Harbor Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Bull Harbor Capital’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$824K Sell
14,406
-4,801
-25% -$263K 0.16% 188
2026
Q1 		$1.09M Buy
+19,207
New +$1.12M 0.29% 95

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Bull Harbor Capital's BMRN Position: Q2 2026 in Review

Bull Harbor Capital reduced its BioMarin Pharmaceuticals (BMRN) stake by 25% in Q2 2026, selling an estimated $263K and leaving 14,406 shares worth $824K. The position accounts for 0.16% of the portfolio, ranked #188.

Bull Harbor Capital first reported a position in BMRN in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.09M in Q1 2026. 564 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Bull Harbor Capital held 14,406 shares of BioMarin Pharmaceuticals worth $824K as of Q2 2026.
  • Bull Harbor Capital sold 4,801 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $263K.
  • BioMarin Pharmaceuticals made up 0.16% of Bull Harbor Capital's portfolio in Q2 2026, its #188 holding.
  • Bull Harbor Capital first reported a position in BioMarin Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Bull Harbor Capital's BioMarin Pharmaceuticals position peaked at $1.09M in Q1 2026.
  • 564 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Bull Harbor Capital's 13F filing for Q2 2026, filed 10 Aug 2026.